Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) Bundle
Who is buying into Zhejiang Jiuzhou Pharmaceutical-and why? As of September 15, 2025, the cap table shows 21 institutional investors holding 2,549,035 shares (≈0.29% of outstanding), with major positions from Vanguard Emerging Markets (VEIEX), Vanguard Total International (VGTSX) and Dimensional Emerging Markets Value Fund alongside a retail majority; institutional holdings total about $4.83 million based on a CN¥20.01 share price that day while the average institutional allocation is just 0.0037% and the number of such investors fell by 12.50% in the latest quarter-facts that sit beside Jiuzhou's operational strengths including a reported net margin of ≈11.7%, analyst forecasts projecting CN¥5.80 billion in 2025 revenue (a 12% increase), year-over-year revenue growth of 9.03%, and a market capitalization of CN¥16.08 billion as of December 12, 2025 (up 31.32% year-over-year), all within the context of strategic expansion into asymmetric catalysts and lithium battery materials-details that invite a closer look at who's betting on Jiuzhou's next chapter
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) - Who Invests in Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) and Why?
- Institutional footprint: As of September 15, 2025, 21 institutional investors hold 2,549,035 shares, ~0.29% of outstanding shares.
- Largest institutional holders:
- Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX)
- Vanguard Total International Stock Index Fund Investor Shares (VGTSX)
- Dimensional Emerging Markets Value Fund
- Retail dominance: Individual investors own the bulk of shares, signaling strong retail appetite for pharmaceutical names.
| Holder Type | Shares Held | % of Outstanding Shares | Representative Investors / Notes |
|---|---|---|---|
| Institutional | 2,549,035 | 0.29% | VEIEX, VGTSX, Dimensional EM Value |
| Individual / Retail | Majority | ~99.71% | High retail participation in China domestic market |
| Total Outstanding (approx.) | ~880 million shares | 100% | Derived from institutional % and share count |
- Investment motivations - why these investors buy:
- Diversified EM exposure: Passive/global funds (Vanguard) include Zhejiang Jiuzhou for emerging-market/pharma weighting.
- Growth via strategic diversification: The company's moves into asymmetric catalysts and lithium battery materials attract investors targeting adjacent high-margin industrial/chemical growth beyond traditional pharma.
- Attractive profitability: Consistent revenue growth and a net margin around 11.7% appeal to investors seeking stable returns.
- Positive forward guidance: Analyst consensus forecasts 2025 revenue of CN¥5.80 billion (≈ +12% YoY), supporting risk-on allocations.
- Portfolio fit:
- Index/ETF investors - for broad EM pharma exposure (passive ownership via VEIEX, VGTSX).
- Value/growth funds - for improving margins and niche-materials upside (Dimensional and similar managers).
- Retail traders - for sector conviction and domestic market familiarity.
Institutional Ownership and Major Shareholders of Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS)
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) shows very limited institutional participation as of September 15, 2025, with institutional investors holding a total of 2,549,035 shares (≈0.29% of outstanding shares). The following points summarize the institutional profile and indicate who the principal institutional names are and what the aggregate data imply for investor interest and positioning.- Total institutional shares: 2,549,035 (≈0.29% of outstanding shares).
- Total value of institutional holdings: approximately $4.83 million (based on CN¥20.01 share price on 2025-09-15; aggregate CN¥ value ≈ CN¥51,006,190.35).
- Largest named institutional holders (representative funds showing exposure): Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX), Vanguard Total International Stock Index Fund Investor Shares (VGTSX), Dimensional Emerging Markets Value Fund.
- Average institutional portfolio allocation to Jiuzhou Pharmaceutical: 0.0037% (modest weight relative to total portfolios).
- Number of institutional investors fell by 12.50% in the most recent quarter (indicating net institutional outflows or rebalancing away from the stock).
- Institutional ownership is minimal relative to typical pharmaceutical-sector peers, suggesting a cautious institutional stance.
| Metric | Value |
|---|---|
| Institutional shares (count) | 2,549,035 |
| % of outstanding shares (institutional) | 0.29% |
| Share price used (snapshot) | CN¥20.01 (2025-09-15) |
| Aggregate institutional market value (CN¥) | CN¥51,006,190.35 |
| Aggregate institutional market value (USD) | $4.83 million |
| Average institutional portfolio allocation | 0.0037% |
| Quarterly change in number of institutional investors | -12.50% |
- Interpretation of major institutional names: the presence of VEIEX, VGTSX and Dimensional Emerging Markets Value Fund points to interest from broad emerging-market and international index/quantitative managers rather than specialist biotech or domestic Chinese healthcare active funds.
- Implication: low absolute institutional ownership and very small average portfolio weights imply limited sell-side coverage reliance and potential liquidity sensitivity to large trades.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) - Key Investors and Their Impact on Zhejiang Jiuzhou Pharmaceutical Co., Ltd
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) has attracted notable allocations from large, diversified emerging‑markets and international equity funds. These institutional investors bring capital, governance light‑touch scrutiny, and credibility that help support Jiuzhou's market valuation and strategic expansion into higher‑value specialty chemicals and materials (asymmetric catalysts, lithium battery materials).- Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX) - a core passive EM index holding, signaling confidence in Jiuzhou as part of emerging‑market growth exposure.
- Vanguard Total International Stock Index Fund Investor Shares (VGTSX) - inclusion reflects appeal to global/international diversification portfolios seeking China exposure beyond the A‑share domestic investor base.
- Dimensional Emerging Markets Value Fund - an active value manager's position, implying a view that Jiuzhou may be attractively valued relative to cash‑flows, technology niche positioning, or R&D pipeline potential.
| Institution / Fund | Investor Type | Stated Rationale | Estimated Holding (range) | Potential Impact |
|---|---|---|---|---|
| Vanguard Emerging Markets Stock Index Fund (VEIEX) | Passive index (EM) | Track EM benchmark; capture China small‑to‑mid cap growth | 0.05%-0.5% of fund NAV | Steady, low‑turnover demand; supports liquidity and valuation floors |
| Vanguard Total International Stock Index Fund (VGTSX) | Passive international | Broad international diversification; exposure to Chinese industrials/chemicals | 0.01%-0.2% of fund NAV | Broadens investor base outside domestic A‑shares; increases visibility to global asset allocators |
| Dimensional Emerging Markets Value Fund | Active value manager | Seeks undervalued EM equities with catalysts for re‑rating | 0.02%-0.4% of fund NAV | Potential for larger, conviction‑driven positions; may drive engagement and re‑rating narratives |
- Improved market credibility with international asset managers, aiding access to foreign capital channels.
- Reduced volatility when passive funds provide a base level of buy demand tied to index rebalances.
- Active investor interest (e.g., Dimensional) can stimulate analyst coverage and investor due diligence, increasing likelihood of additional institutional inflows.
- Alignment between investor mandates (emerging markets / international diversification / value) and Jiuzhou's strategic pivot into asymmetric catalysts and lithium battery materials supports stories of secular growth beyond legacy pharma revenues.
| Metric | Value |
|---|---|
| Market capitalization | CN¥16.08 billion |
| Primary investor types | Passive EM index funds, passive international funds, active EM value funds |
| Strategic growth areas cited | Asymmetric catalysts; lithium battery materials; specialty chemical intermediates |
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) - Market Impact and Investor Sentiment
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) has registered measurable market traction as of December 12, 2025, driven by revenue growth, strategic pivots into higher-value specialty materials, and analyst-updated forecasts that reinforce investor confidence.- Market capitalization: CN¥16.08 billion (31.32% increase year-over-year as of 2025-12-12)
- Reported revenue growth: +9.03% year-over-year for the most recent fiscal period
- Analyst 2025 revenue consensus: CN¥5.80 billion (implying ~12% growth year-over-year)
- Strategic expansion: asymmetric catalysts and lithium battery materials targeting higher-margin niches
- Institutional ownership: relatively low versus pharmaceutical peers, suggesting cautious institutional positioning
| Metric | Value (as of 2025-12-12) | Context / Implication |
|---|---|---|
| Market Capitalization | CN¥16.08 billion | Up 31.32% YoY - signals positive market sentiment |
| Revenue (Trailing 12 months) | Reported with +9.03% YoY growth | Stabilizing top-line expansion supporting valuations |
| Analyst 2025 Revenue Forecast | CN¥5.80 billion | ~12% projected growth - underpins investor optimism |
| Core Growth Areas | Asymmetric catalysts; lithium battery materials | Higher-value, specialty segments improving margin and diversification |
| Institutional Ownership | Low relative to pharma peers | Possible caution among institutional investors despite positive fundamentals |
- Growth investors: attracted by double-digit market-cap appreciation and analyst revenue upgrades
- Value-oriented investors: monitoring improving revenue trends and potential margin expansion from specialty products
- Speculative/innovation-focused investors: drawn to asymmetric catalyst and lithium-material exposure as higher-return opportunities
- Institutional investors: currently more cautious, reflected in below-average institutional holdings versus sector peers
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.